Back to Research

Organization profile

Phialogics AG

Phialogics is a preclinical-stage Swiss biotechnology company specialized in engineering next-generation biologics to rebalance the immune system in chronic and acute inflammation. Its proprietary platform modifies immunoglobulin receptor domains (IgVs) to create highly selective immune checkpoint activators for the treatment of autoimmune diseases.

Allschwil, SwitzerlandFounded 2021

Overview

1. Executive Summary (Confidence: High)

Phialogics AG, founded in 2021 and based in Allschwil, Switzerland, is an innovative spin-off from the Fraunhofer Institute of Translational Medicine and Pharmacology (ITMP).[1] The company is dedicated to providing disease-modifying solutions for patients with autoimmune conditions through a unique platform that modifies IgV domains to achieve unprecedented precision in immune modulation.[3] In April 2023, the organization successfully closed a pre-seed financing round led by High-Tech Gründerfonds (HTGF) and has since been part of the BaseLaunch portfolio.[2] Their technology targets the root cause of autoimmune tissue injury by replicating natural protein-protein interactions, moving away from systemic immunosuppression toward localized immune tolerance.[4]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.